Recently, ROCK1 is found as a novel Rac1 effector [64], and TRPV4 targets the AKT for phosphorylation, promotes migration and invasion through AKT/Rac1 signaling in glioma [65]. Here, TRPV4 is linked to central nervous system cancer.